trastuzumab (Saituo / TQB211 / TQ B211)

✓ Approved

Sino Biopharmaceutical Co., Ltd · ERBB2 · Monoclonal Antibodies

What is trastuzumab?

trastuzumab is a monoclonal antibodies developed by Sino Biopharmaceutical Co., Ltd. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand Names	Saituo, TQB211, TQ B211
Company	Sino Biopharmaceutical Co., Ltd
Drug Class	Monoclonal Antibodies, Antibody
Molecular Target	ERBB2
Route	Injectable (Others), Intravenous (IV)
Status	Approved

Sources: ClinicalTrials.gov, Sino Biopharmaceutical Co., Ltd

Mechanism of Action

Molecular Targets

trastuzumab acts on 1 molecular target:

ERBB2

erb-b2 receptor tyrosine kinase 2 (NEU, CD340)

Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

trastuzumab is developed for 3 unique indications across 1 therapeutic area.

Therapeutic Area	Condition	Phase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Breast cancer	✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Gastric cancer	✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Oesophageal carcinoma	Preclinical